Minlin Jiang and colleagues built a FOXP3-based immune risk model to predict I–III stage SCLC’s recurrence, and the model scored 0.656–0.737 AUC in the train cohort and 0.608–0.714 in the validation cohort (54). Here, FOXP3 is linked to small cell lung carcinoma.